Phase I part

Biologic

KKyushu University

Phase I part is one of 50 biologic programs targeting Intestinal Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

94 competitors in Intestinal Cancer

#DrugCompanyPhaseTrials

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Eloxatin

Teva

Phase 2

6 3

Keytruda

Merck & Co.

Phase 2

3 4

Camptosar

Pfizer

Phase 2

2 5

Beyfortus

BeiGene

Phase 2

1 6

Fudr

Pfizer

Phase 2

1 7

Pemazyre

Incyte

Phase 2

1 8

Tukysa

Pfizer

Phase 2

1 9

Tecentriq

Roche

Phase 2

1 10

Adrucil

EElorac, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Intestinal Cancer

NCT05438459

Clinical

Trials by Indication[1]

Intestinal Cancer1 trial

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

Recruiting·KKyushu University·Phase 1/2·NCT05438459·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Phase I part. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phase I part compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phase I part. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyushu University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: KKyushu University

Phase I part

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Intestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News